Purpose of trial
The aim of the trial is to compare 2 different chemotherapy regimens (combinations of drugs) as a first treatment for people with T-cell lymphoma.
CHOP chemotherapy is often used as first-line treatment for T-cell lymphoma. People whose lymphoma relapses (comes back) might be treated with GEM-P. Researchers want to find out which of these 2 chemotherapy regimens works best in people who haven’t had any previous treatment for their T-cell lymphoma. They also want to compare the side effects (unwanted effects of treatment) of the 2 regimens.
People with the following types of T-cell lymphoma might be able to enter this trial:
- peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
- anaplastic large cell lymphoma (ALCL) that is systemic (affecting your whole body), not cutaneous (only in the skin), and doesn’t have a marker called ‘ALK’ on the cell surface - ALK negative ALCL
- angioimmunoblastic T-cell lymphoma (AITL)
- enteropathy-associated T-cell lymphoma (EATL)
- hepatosplenic gamma/delta T-cell lymphoma.
Participants are randomised to decide which chemotherapy regimen they have:
- CHOP includes the drugs cyclophosphamide, doxorubicin, vincristine and prednisolone
- GEM-P includes the drugs gemcitabine, cisplatin and methylprednisolone.
You can’t choose which treatment you have and neither can your doctor. You are told which treatment you are having and given information about it.
In this trial, you have most of the drugs intravenously (through a drip into a vein). You have the steroid drugs prednisolone and methylprednisolone as tablets.
For CHOP, the drugs are given in 3 week cycles for up to 6 cycles of treatment.
For GEM-P, the drugs are given in 4 week cycles for up to 4 cycles of treatment.
In a cycle of treatment, you have the drug on some days followed by a rest period to allow your body to recover before the next cycle.
Who can enter
This trial is no longer recruiting participants.
More information about this trial is available at clinicaltrials.gov.